Lyell Immunopharma Inc. Aktie

Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.